Uterine
fibroids, also
known as leiomyomas or myomas, are non-cancerous growths that develop from the
muscle tissue of the uterus. The size, shape, and location of fibroids can vary
greatly. They may be present inside the uterus on its outer surface, or within
its wall, or attached to it by a stem-like structure.
Access
Detailed Report Summary: https://www.pharmaproff.com/report/uterine-fibroids-therapeutics-pipeline-analysis
A fibroid
may remain very small for a long time and suddenly grow rapidly, or grow slowly
over a number of years. It usually affects women between the age of 30 to 40
years, but can occur at any age. Uterine fibroids may have various symptoms,
such as change in menstruation, anaemia, abdominal cramps, constipation, pain
during sex, rectal pain, and difficulty urinating or frequent urination. It is
diagnosed through ultrasonography, hysteroscopy, hysterosalpingography, and
sonohysterography. Some medications are known to reduce heavy bleeding and
painful periods, caused due to this condition.
Request
to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1150
The drug
candidates in uterine fibroids disease pipeline include, but are not limited
to, Elagolix, OBE2109, and Proellex. Some of the companies having drugs in the
uterine fibroids disease pipeline are Neurocrine Biosciences Inc., Abbvie Inc.,
and ObsEva SA.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment